alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 501–525 of 546 studies in Vascular contributions (page 21 of 22) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Vascular contributions” covers

Vascular contributions — How blood vessel health, small-vessel disease and stroke risk contribute to dementia and cognitive decline.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2016-06-20

Matrix metalloproteinases are versatile endopeptidases with many different functions in the body in health and disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Trends in neurosciences 2001-12-01

Disruption of the tight junctions (TJs) of the blood-brain barrier (BBB) is a hallmark of many CNS pathologies, including stroke, HIV encephalitis, Alzheimer's disease, multiple sclerosis and bacterial meningitis. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Perivascular nerves and the regulation of cerebrovascular tone

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of applied physiology (Bethesda, Md. : 1985) 2006-03-01

Brain perfusion is tightly coupled to neuronal activity, is commonly used to monitor normal or pathological brain function, and is a direct reflection of the interactions that occur between neuronal signals and blood vessels. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropathology and applied neurobiology 2008-01-16

Elimination of interstitial fluid and solutes plays a role in homeostasis in the brain, but the pathways are unclear. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of molecular biology 2001-10-01

Amyloid beta-protein (Abeta) assembly into toxic oligomeric and fibrillar structures is a seminal event in Alzheimer's disease, therefore blocking this process could have significant therapeutic benefit. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

The blood-brain barrier in brain homeostasis and neurological diseases

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biochimica et biophysica acta 2008-11-11

Brain endothelial cells are unique among endothelial cells in that they express apical junctional complexes, including tight junctions, which quite resemble epithelial tight junctions both structurally and functionally. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1993-11-01

Reinvestigation of the chemical structure of beta-amyloid peptide (A beta) deposits in the vascular tissue of Alzheimer disease brains revealed that the 42-residue form A beta-(1-42), rather than the more soluble A beta-(1-40) form, is the predominant peptide. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2006-11-22

The molecular mechanism underlying the pathogenesis of the majority of cases of sporadic Alzheimer's disease (AD) is unknown. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuron 2008-07-01

As a disease-modifying approach for Alzheimer's disease (AD), clioquinol (CQ) targets beta-amyloid (Abeta) reactions with synaptic Zn and Cu yet promotes metal uptake. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of molecular biology 1992-06-01

The A4 or beta-peptide (39 to 43 amino acid residues) is the principal proteinaceous component of amyloid deposits in Alzheimer's disease. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Healthy dietary intake diminishes the effect of cerebral small vessel disease on cognitive performance in older adults

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Frontiers in Neurology 2025-03-06

Dietary intake moderated the association between several cSVD biomarkers and MoCA scores such that the expected negative association between cSVD biomarkers and cognition was seen at low levels of healthy dietary intake, but not at medium or high levels. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Greater White Matter Hyperintensities and More Severe Cognitive Dysfunction in Mild Cognitive Impairment With Motoric Cognitive Risk Syndrome

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Journal of Korean Medical Science 2025-01-01

< 0.0036), the MCRS group exhibited significantly worse performance on word list memory, word list recall, and MMSE-KC compared to the MCI group without slow gait. 2 key findings →

Participants: 81 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of PM2.5 on Cardiovascular Disease, Dementia, and Stroke in Older Kidney Transplant Recipients

✓ Peer-reviewed alzhub usefulness score 34 out of 100. American Journal of Transplantation 2025-01-01

Exposure to fine particulate matter (PM ) pollution is associated with negative health outcomes including dementia, cardiovascular disease (CVD), and stroke due to increased levels of oxidative stress and inflammation among community-dwelling older adults. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Increased iron deposition in putamen and substantia nigra correlates with cognitive function in cerebral small vessel disease: A quantitative susceptibility mapping study

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Cerebral Blood Flow & Metabolism 2025-11-12

Cerebral small vessel disease (CSVD) is a major contributor to stroke and dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Retinal vessel density using optical coherence tomography angiography as a potential biomarker in patients with cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 32 out of 100. The Egyptian Journal of Neurology Psychiatry and Neurosurgery 2025-05-26

OCTA is a handy, noninvasive tool that enables the visualization of diminished retinal microvascular density in cases of early CSVD. 3 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed